Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
55.35
+1.78 (3.32%)
At close: Jun 23, 2026, 4:00 PM EDT
55.45
+0.10 (0.18%)
After-hours: Jun 23, 2026, 6:45 PM EDT
Royalty Pharma Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Royalty Pharma stock has a consensus rating of "Buy" and an average price target of $59.25. The average 1-year stock price forecast is 7.05% higher than the current stock price, while the lowest is $46 (-16.89%) and the highest is $66 (+19.24%).
Price Target: $59.25 (+7.05%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Royalty Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Hold | 0 | 1 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $66 | Buy | Maintains | $66 | +19.24% | May 26, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $63 → $64 | Buy | Maintains | $63 → $64 | +15.63% | May 7, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $50 → $58 | Buy | Maintains | $50 → $58 | +4.79% | May 7, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $54 → $62 | Buy | Maintains | $54 → $62 | +12.01% | May 7, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Reiterates $51 → $59 | Buy | Reiterates | $51 → $59 | +6.59% | May 7, 2026 |
Financial Forecast
Revenue This Year
3.43B
from 2.38B
Increased by 44.24%
Revenue Next Year
3.66B
from 3.43B
Increased by 6.67%
EPS This Year
5.12
from 4.83
Increased by 5.96%
EPS Next Year
5.61
from 5.12
Increased by 9.70%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.5B | ||
| Avg | 3.4B | ||
| Low | 3.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 47.7% | ||
| Avg | 44.2% | ||
| Low | 39.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.33 | ||
| Avg | 5.12 | ||
| Low | 4.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 10.4% | ||
| Avg | 6.0% | ||
| Low | -4.3% |